E-Book

E-Book 3rd Congress

  • Evaluation of PDGFRB expression level in childhood Iranian Patients with ALL
  • Tarlan Nayebbagher,1 Seyed Jalal Zargar,2,* Vahid Reza Yassaee,3
    1. Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    2. Department of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran
    3. Genomic Research Center, Taleghani Hospital, Shahid Arabi Street, Yaman Avenue, Velenjak, Tehran, Iran


  • Introduction: Correlation between gene Expression and recurrence as a treatment failure in pediatric patients with Acute Lymphoblastic Leukemia (ALL) is an unsolved problem in scientific associations. In this study, we evaluate predictive value of PDGFR expression level for estimating recurrence in Iranian Pediatric Patients with ALL and its MRD level after chemotherapy. ALL MRD refers to the presence of residual Leukemia cells following the achievement of complete remission, but below the limit of detection using conventional morphologic assessment; Patients with detectable MRD have an increased likelihood of relapse. MRD has emerged as the strongest independent predictor of individual patient outcome and is crucial for risk stratification and if is evaluated with genetic novel biomarkers, will be effective at target therapy and increase in patient’s survival rate.
  • Methods: Material and Methods: Iranian pediatric patients with approved ALL enrolled in this study as four groups of new case(ALL) and control(without ALL), patients who were in post-induction phase, and patients in relapse phase. Real-time Polymerase Chain Reaction reacting was done with GAPDH for expressing PDGFRB gene. Gathered data, analyzed with SPSS version 22 and REST 2009 software. Peripheral Blood (PB) of fifty pediatric B, BCP, and ph-like ALL patients (Median age: Years) at new diagnosis clinical stages, and after their follow-up treatment in post-induction phase were collected. Thirty healthy children were included as a control group and twenty patients at relapse phase, in addition. PDGFRB gene expressing was analyzed by RT-PCR. The correlation analysis was performed between PDGFR gene expression and patients demographic and laboratory characteristics. GAPDH housekeeping gene was used as an internal control.
  • Results: The results showed that PDGFRB gene expression was significantly up regulated in new diagnosis patients and relapse phases compared to the control group. PDGFRB gene expression in Post-Induction phase was significantly lower than its level at new diagnosis stage (p<0.001). Moreover PDGFRB gene was significantly up regulated in relapse phase compared to the new diagnosis. One hundred samples (Fifty new case ALL and Fifty controls) enrolled. Beside on PDGFRB expression were detected in twenty pediatric patients with relapse. PDGFRB had significant relation with high-risk patients of new case ALL and lead to poor prognosis.
  • Conclusion: PDGFRB levels could be a potential biomarker of therapy response in remission induction therapy for pediatric ALL. Designed expression pattern have the predictive value for estimating of conferring relapse in Iranian pediatric patients with diagnosed ALL. The authors suggest of designing a multiple childhood malignancy center project to evaluate this pattern in a cohort study.
  • Keywords: Gene Expression, ALL, PDGFRB gene, MRD, Prognostic marker